[go: up one dir, main page]

MA71692A - Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique - Google Patents

Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique

Info

Publication number
MA71692A
MA71692A MA71692A MA71692A MA71692A MA 71692 A MA71692 A MA 71692A MA 71692 A MA71692 A MA 71692A MA 71692 A MA71692 A MA 71692A MA 71692 A MA71692 A MA 71692A
Authority
MA
Morocco
Prior art keywords
milvexian
prevention
treatment
ischemic stroke
ischemic
Prior art date
Application number
MA71692A
Other languages
English (en)
Inventor
Christopher Nessel
Danshi LI
Charlotte JONES-BURTON
Alexei PLOTNIKOV
Vidya Liyanage PERERA
Anja KAHL
Samira J. MERALI
Puneet MOHAN
Yshai YAVIN
Original Assignee
Bristol-Myers Squibb Company
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company, Janssen Pharmaceutica Nv filed Critical Bristol-Myers Squibb Company
Publication of MA71692A publication Critical patent/MA71692A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71692A 2022-08-01 2023-08-01 Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique MA71692A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263370031P 2022-08-01 2022-08-01
US202263401361P 2022-08-26 2022-08-26
US202263379848P 2022-10-17 2022-10-17
US202363498945P 2023-04-28 2023-04-28
EP23761286.6A EP4565231A1 (fr) 2022-08-01 2023-08-01 Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
PCT/US2023/029178 WO2024030409A1 (fr) 2022-08-01 2023-08-01 Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique

Publications (1)

Publication Number Publication Date
MA71692A true MA71692A (fr) 2025-05-30

Family

ID=87801450

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71692A MA71692A (fr) 2022-08-01 2023-08-01 Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique

Country Status (12)

Country Link
EP (1) EP4565231A1 (fr)
JP (1) JP2025525915A (fr)
KR (1) KR20250043544A (fr)
CN (1) CN119816305A (fr)
CA (1) CA3263789A1 (fr)
CL (1) CL2025000255A1 (fr)
IL (1) IL318260A (fr)
MA (1) MA71692A (fr)
MX (1) MX2025000873A (fr)
TW (1) TW202423444A (fr)
UY (1) UY40381A (fr)
WO (1) WO2024030409A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024257779A1 (en) * 2023-04-19 2025-12-04 Bristol-Myers Squibb Company Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome
AU2024258924A1 (en) * 2023-04-19 2025-11-27 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112021020257A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico
CA3179957A1 (fr) 2020-04-10 2021-10-14 Bristol-Myers Squibb Company (9r,135s)-13-{4-[5-chloro-2-(4-chloro-1h,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02·6]octadeca-1(18) ,2(6),4,14,16-pentaen-8-one
TW202229280A (zh) 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 (6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之製備方法
EP4401736A1 (fr) * 2021-09-17 2024-07-24 Bristol-Myers Squibb Company Milvexian pour la prévention et le traitement de troubles thromboemboliques

Also Published As

Publication number Publication date
TW202423444A (zh) 2024-06-16
UY40381A (es) 2024-01-31
CL2025000255A1 (es) 2025-06-13
MX2025000873A (es) 2025-03-07
KR20250043544A (ko) 2025-03-28
WO2024030409A1 (fr) 2024-02-08
CA3263789A1 (fr) 2024-02-08
EP4565231A1 (fr) 2025-06-11
IL318260A (en) 2025-03-01
CN119816305A (zh) 2025-04-11
JP2025525915A (ja) 2025-08-07

Similar Documents

Publication Publication Date Title
MA71692A (fr) Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
FR22C1063I2 (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
EP4221604A4 (fr) Dispositifs intravasculaires de limitation d'écoulement pour le traitement d'un ?dème
EP4058037A4 (fr) Thérapie à base de fibroblastes pour le traitement et la prévention d'un accident vasculaire cérébral
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA50073A (fr) Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
EP4157324A4 (fr) Analogue de pth pour le traitement de l'hypoparathyroïdie
EP3927706A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles prolifératifs
EP4366720A4 (fr) Utilisation de bêta-hydroxybutyrates pour le traitement ou la prévention d'anévrismes et de dissections
EP3968989A4 (fr) Composé pour le traitement de la goutte ou de l'hyperuricémie
EP3876967A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention d'une dysbiose
EP4297868A4 (fr) Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
EP4157341A4 (fr) Peptides pour la prévention et le traitement de la covid-19
EP3931178A4 (fr) Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire
EP3777848A4 (fr) Composition pour la prévention ou le traitement d'un accident vasculaire cérébral
EP3936124A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies neurologiques
EP3883552A4 (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
EP3785718A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie infectieuse de flavivirus
EP4052694A4 (fr) Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire
EP4127233A4 (fr) Dosages pour la détection d'agents pathogènes
EP4232075A4 (fr) Composés, compositions et méthodes d'utilisation pour le traitement de spondylodèses
EP4238561A4 (fr) Utilisation de zanamivir dans la préparation d'un médicament pour le traitement ou la prévention de la prééclampsie
EP4230652A4 (fr) Anticorps anti-oscar pour la prévention ou le traitement de l'arthrose
EP4349341A4 (fr) Préparation pharmaceutique pour la prévention ou le traitement de la fibrose pulmonaire
EP4185304A4 (fr) Hydrogel thérapeutique pour l'administration de lymphocytes t car